BRPI1005670A8 - composições adjuvantes e processos de uso. - Google Patents
composições adjuvantes e processos de uso.Info
- Publication number
- BRPI1005670A8 BRPI1005670A8 BRPI1005670A BRPI1005670A BRPI1005670A8 BR PI1005670 A8 BRPI1005670 A8 BR PI1005670A8 BR PI1005670 A BRPI1005670 A BR PI1005670A BR PI1005670 A BRPI1005670 A BR PI1005670A BR PI1005670 A8 BRPI1005670 A8 BR PI1005670A8
- Authority
- BR
- Brazil
- Prior art keywords
- processes
- adjuvant compositions
- adjuvant
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20431609P | 2009-01-05 | 2009-01-05 | |
PCT/US2010/020053 WO2010078556A1 (en) | 2009-01-05 | 2010-01-04 | Adjuvant compositions and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI1005670A2 BRPI1005670A2 (pt) | 2017-03-28 |
BRPI1005670A8 true BRPI1005670A8 (pt) | 2017-12-26 |
Family
ID=42310234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1005670A BRPI1005670A8 (pt) | 2009-01-05 | 2010-01-04 | composições adjuvantes e processos de uso. |
Country Status (7)
Country | Link |
---|---|
US (4) | US8425922B2 (pt) |
EP (1) | EP2384120B1 (pt) |
CN (2) | CN102307477B (pt) |
AU (1) | AU2010203223B9 (pt) |
BR (1) | BRPI1005670A8 (pt) |
CA (1) | CA2748788C (pt) |
WO (1) | WO2010078556A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2066344B2 (en) * | 2006-09-07 | 2016-06-29 | GlaxoSmithKline Biologicals S.A. | Inactivated Poliovirus combination vaccine |
CN102307477B (zh) | 2009-01-05 | 2015-07-29 | 埃皮托吉尼西斯股份有限公司 | 佐剂组合物及使用方法 |
WO2012037193A2 (en) * | 2010-09-17 | 2012-03-22 | Brassica Protection Products Llc | Formulations for treatment with glucosinolate |
TR201910409T4 (tr) | 2011-03-11 | 2019-08-21 | Km Biologics Co Ltd | Sitrülin barındıran adjuvan bileşimi. |
WO2012145491A2 (en) * | 2011-04-20 | 2012-10-26 | Jason Fisher | Composition and method for enhancing an immune response |
CA2839507A1 (en) * | 2011-06-24 | 2012-12-27 | Epitogenesis Inc. | Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
CA2842745C (en) * | 2011-07-26 | 2018-01-09 | Wm. Wrigley Jr. Company | Compositions containing zinc salts and isothiocyanates for reduction of oral volatile sulfur compounds (vscs) |
EP2679225A1 (de) * | 2012-06-26 | 2014-01-01 | Universitätsklinikum Freiburg | Pharmazeutische Zusammensetzung mit synergistischer Wirkung von direkten Katalaseinhibitoren und zur Katalasezerstörung führenden Modulatoren des NO-Stoffwechsels oder der extrazellulären Superoxidanionenproduktion |
CN104640539B (zh) * | 2012-09-21 | 2019-08-02 | 雀巢产品有限公司 | 植物酚及其在治疗或预防嗜酸性食管炎中的用途 |
US10300258B2 (en) * | 2012-10-30 | 2019-05-28 | Tara Chand Singhal | Apparatus and method for natural cure of middle ear infections without antibiotics |
CL2013001774A1 (es) * | 2013-06-18 | 2014-08-01 | Univ Santiago Chile | Formulacion con actividad inmunoestimulante/adyuvante que comprende alpinona , dimetil sulfóxido y suero fisiológico; uso de dicha formulación para preparar vacunas para vertebrados. |
WO2016203025A1 (en) * | 2015-06-17 | 2016-12-22 | Curevac Ag | Vaccine composition |
JP6995756B2 (ja) * | 2015-12-23 | 2022-02-04 | ノバルティス アーゲー | レチノイン酸を含む水中油型エマルジョン |
CN106798920B (zh) * | 2017-01-23 | 2018-10-12 | 北京康宝利华生物科技有限公司 | 一种复合免疫佐剂及其制备方法和应用 |
CN107670032A (zh) * | 2017-10-27 | 2018-02-09 | 贵州福斯特生物科技有限公司 | 家禽油乳剂灭活疫苗佐剂及其相应疫苗的制备方法 |
WO2020161653A2 (en) * | 2019-02-07 | 2020-08-13 | Benny Antony | Mustard extract enriched with sinigrin having increased bioactivity and bioavailability of allyl isothiocyanate |
AU2020242717A1 (en) | 2019-03-20 | 2021-10-28 | Advagene Biopharma Co., Ltd. | Method of modulating mucosal immunogenicity |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US522130A (en) * | 1894-06-26 | Oil from wool | ||
US3149036A (en) * | 1961-10-16 | 1964-09-15 | Merck & Co Inc | Adjuvant vaccine with aluminum monostearate, mannide monooleate, vegetable oil, and an aqueous phase immunolgical agent |
DE3241113A1 (de) * | 1982-11-06 | 1984-05-10 | Bayer Ag, 5090 Leverkusen | Vakzinen mit zuschlagstoffen |
US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5135855A (en) | 1986-09-03 | 1992-08-04 | The United States Of America As Represented By The Department Of Health And Human Services | Rapid, versatile and simple system for expressing genes in eukaryotic cells |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
DE10399031I1 (de) | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
EP0378881B1 (en) | 1989-01-17 | 1993-06-09 | ENIRICERCHE S.p.A. | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
JPH0832638B2 (ja) * | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
FR2658432B1 (fr) | 1990-02-22 | 1994-07-01 | Medgenix Group Sa | Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation. |
WO1992001070A1 (en) | 1990-07-09 | 1992-01-23 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
ATE128628T1 (de) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff. |
MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
US5591771A (en) * | 1991-12-17 | 1997-01-07 | Michel Fockerman | Use of propolis components as an adjuvant |
US5229130A (en) | 1991-12-20 | 1993-07-20 | Cygnus Therapeutics Systems | Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems |
IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
US5591601A (en) | 1993-05-14 | 1997-01-07 | Ohio University Edison Animal Biotechnology Institute | DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system |
US5614413A (en) | 1993-07-01 | 1997-03-25 | The Uab Research Foundation | Encapsidated recombinant poliovirus nucleic acid and methods of making and using same |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5676950A (en) | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
US5744137A (en) * | 1995-02-06 | 1998-04-28 | The United States Of America As Represented By The Secretary Of The Agriculture | Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
EP0879284B1 (en) | 1996-01-30 | 2009-07-29 | The Regents of The University of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
GB9622660D0 (en) | 1996-10-31 | 1997-01-08 | Biocine Spa | Immunogenic detoxified mutant toxin |
US6761914B2 (en) * | 1997-05-27 | 2004-07-13 | Sembiosys Genetics Inc. | Immunogenic formulations comprising oil bodies |
CA2291483C (en) | 1997-06-06 | 2012-09-18 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
BR9813930A (pt) | 1997-11-06 | 2006-12-19 | Chiron Spa | antìgeno neisserial |
CA2307846A1 (en) | 1997-11-21 | 1999-06-03 | Genset S.A. | Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
BR9814912A (pt) | 1997-11-28 | 2000-10-03 | Genset Sa | Sequência genÈmica e polipeptìdeos de chlamydia trachomatis, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção |
EP1047784B2 (en) | 1998-01-14 | 2015-03-18 | Novartis Vaccines and Diagnostics S.r.l. | Neissera meningitidis antigens |
NZ532665A (en) | 1998-05-01 | 2005-11-25 | Inst Genomic Research | Neisseria meningitidis antigens and compositions |
MXPA01003557A (es) | 1998-10-09 | 2004-04-05 | Chiron Corp | Secuencias genomicas de neisseria y metodos para su uso. |
AU1722300A (en) | 1998-11-12 | 2000-05-29 | Regents Of The University Of California, The | Chlamydia pneumoniae genome sequence |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
US6329201B1 (en) | 1998-12-31 | 2001-12-11 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
BR0009163A (pt) | 1999-03-19 | 2001-12-26 | Smithkline Beecham Biolog | Vacina |
JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ, インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンaタンパク質キャリア |
GB9923060D0 (en) | 1999-09-29 | 1999-12-01 | Chiron Spa | Vaccine |
EP2275129A3 (en) | 2000-01-17 | 2013-11-06 | Novartis Vaccines and Diagnostics S.r.l. | Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
ES2312447T3 (es) | 2000-05-31 | 2009-03-01 | Novartis Vaccines And Diagnostics, Inc. | Procedimiento para la purificacion de particulas de replicon alfavirus. |
DE60136928D1 (de) | 2000-06-16 | 2009-01-22 | Sembiosys Genetics Inc | Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme |
DE60139690D1 (de) | 2000-07-03 | 2009-10-08 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia pneumoniae |
EP1228769A1 (de) | 2001-02-02 | 2002-08-07 | Jörg-Peter Prof. Schür | Symbiontisches Regenerativum |
GB0216371D0 (en) | 2002-07-13 | 2002-08-21 | Rowett Res Inst The | Compounds |
US7544816B2 (en) | 2004-08-19 | 2009-06-09 | The Hong Kong Polytechnic University | (−)-Epigallocatechin gallate derivatives for inhibiting proteasome |
US20060217443A1 (en) | 2005-03-28 | 2006-09-28 | Kimberly-Clark Worldwide, Inc. | Method for preventing and/or treating vaginal and vulval infections |
US20070082073A1 (en) * | 2005-05-18 | 2007-04-12 | University Of South Florida | Catechin Adjuvants |
DE102006035618A1 (de) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
RU2326667C1 (ru) * | 2006-11-09 | 2008-06-20 | Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук | Средство для лечения гнойно-воспалительных заболеваний кожи и мягких тканей различной этиологии |
RU2329790C1 (ru) * | 2006-12-07 | 2008-07-27 | Открытое акционерное общество "Нижегородский химико-фармацевтический завод" | Лечебно-профилактическое средство, обладающее антибактериальным и спермицидным действием |
CN101677588A (zh) * | 2007-02-01 | 2010-03-24 | 加拿大国家研究委员会 | 亲脂性生物活性分子制剂 |
CN101095433B (zh) * | 2007-08-03 | 2010-06-02 | 内蒙古蒙牛乳业(集团)股份有限公司 | 一种适用于1—3岁幼儿食用的液态奶及其生产方法 |
EP3023107A1 (en) | 2008-04-21 | 2016-05-25 | Nanobio Corporation | Nanoemulsion influenza vaccine |
CN102307477B (zh) | 2009-01-05 | 2015-07-29 | 埃皮托吉尼西斯股份有限公司 | 佐剂组合物及使用方法 |
CA2839507A1 (en) | 2011-06-24 | 2012-12-27 | Epitogenesis Inc. | Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
-
2010
- 2010-01-04 CN CN201080006958.1A patent/CN102307477B/zh active Active
- 2010-01-04 AU AU2010203223A patent/AU2010203223B9/en active Active
- 2010-01-04 BR BRPI1005670A patent/BRPI1005670A8/pt not_active IP Right Cessation
- 2010-01-04 WO PCT/US2010/020053 patent/WO2010078556A1/en active Application Filing
- 2010-01-04 EP EP10726828.6A patent/EP2384120B1/en active Active
- 2010-01-04 CN CN201510359905.2A patent/CN105056229A/zh active Pending
- 2010-01-04 CA CA2748788A patent/CA2748788C/en active Active
- 2010-01-04 US US12/651,975 patent/US8425922B2/en active Active
-
2013
- 2013-03-07 US US13/788,847 patent/US9180184B2/en active Active
-
2015
- 2015-07-30 US US14/813,866 patent/US20150335737A1/en not_active Abandoned
-
2016
- 2016-02-17 US US15/045,986 patent/US10765735B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2384120B1 (en) | 2019-12-11 |
AU2010203223B9 (en) | 2015-10-08 |
CN102307477A (zh) | 2012-01-04 |
CA2748788C (en) | 2021-02-09 |
AU2010203223B2 (en) | 2015-09-17 |
US9180184B2 (en) | 2015-11-10 |
US20160158350A1 (en) | 2016-06-09 |
US20130189288A1 (en) | 2013-07-25 |
BRPI1005670A2 (pt) | 2017-03-28 |
EP2384120A1 (en) | 2011-11-09 |
CN102307477B (zh) | 2015-07-29 |
US20150335737A1 (en) | 2015-11-26 |
US20100172941A1 (en) | 2010-07-08 |
CA2748788A1 (en) | 2010-07-08 |
US8425922B2 (en) | 2013-04-23 |
AU2010203223A1 (en) | 2011-07-28 |
WO2010078556A1 (en) | 2010-07-08 |
CN105056229A (zh) | 2015-11-18 |
EP2384120A4 (en) | 2013-12-04 |
US10765735B2 (en) | 2020-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1005670A8 (pt) | composições adjuvantes e processos de uso. | |
BRPI1012533A2 (pt) | composto de piradazinona e uso do mesmo | |
BRPI1005292A2 (pt) | composição de decapagem e uso da composição | |
BRPI0813627A2 (pt) | Peptídio antimicrobiano, composições e métodos de uso | |
BR112012002349A2 (pt) | composto,e, uso do mesmo | |
BRPI0913086A2 (pt) | Composições antimicrobianas e métodos de uso | |
BR112013006016A2 (pt) | compostos de azabenzotiazol, composições e métodos de uso | |
BRPI1006519A2 (pt) | formulação de anticorpos | |
BR112012002331A2 (pt) | composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica | |
BRPI1007494A2 (pt) | composto e uso do mesmo | |
BRPI0920240A2 (pt) | formulação de adjuvante de combinação | |
BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
BRPI1014316A2 (pt) | composição, e, uso de uma composição | |
BR112013010988A2 (pt) | composição fluída e uso | |
FI20096058A0 (fi) | Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä | |
BRPI1012728A2 (pt) | uso de tripeptídeos | |
DK2442771T3 (da) | Silikone-arbehandlingspræparat | |
BRPI1009465A2 (pt) | Formulação | |
BRPI1005919A2 (pt) | composição imunogênica | |
BRPI1006996A2 (pt) | composição, método e uso | |
BRPI1011036A2 (pt) | uso | |
BR112012003152A2 (pt) | composição removedora de oxigênio, artigo,e, uso de composição removedora de oxigênio. | |
BRPI0909223A2 (pt) | uso de catepsaina c | |
BR112012000383A2 (pt) | composições farmacêuticas e formas sólidas | |
BRPI1016245A2 (pt) | Preparação de c-pirazina-metilaminas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |